CorMedix Shares Plunge After 1H Guidance Missed Expectations

Dow Jones

2025/03/25

By Sabela Ojea

Shares of CorMedix Tuesday dropped after the company's outlook for the first half of 2025 disappointed investors despite beating expectations in the fourth quarter.

The stock was down 31% at $7.39 in morning trading, on pace for the largest percent decrease since Aug. 22, when it fell 57%. Shares have dropped 80% over the past 12 months.

The biopharmaceutical company said it expects revenue between $50 million to $60 million for the first half. Analysts polled by FactSet are forecasting revenue of $31 million for the first quarter and $32.6 million for the second quarter, equal to $63.6 million in combined revenue.

The company's outlook implies a deceleration in revenue for the second quarter after it guided for a first-quarter topline performance of more than $33 million.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

March 25, 2025 11:31 ET (15:31 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2522001807"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522001807\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2522001807?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-25 23:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522001807","market":"hk","top_or_hot":-1,"title":"CorMedix Shares Plunge After 1H Guidance Missed Expectations","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of CorMedix Tuesday dropped after the company's outlook for the first half of 2025 disappointed investors despite beating expectations in the fourth quarter. \n</p>\n<p>\n  The stock was down 31% at $7.39 in morning trading, on pace for the largest percent decrease since Aug. 22, when it fell 57%. Shares have dropped 80% over the past 12 months. \n</p>\n<p>\n  The biopharmaceutical company said it expects revenue between $50 million to $60 million for the first half. Analysts polled by FactSet are forecasting revenue of $31 million for the first quarter and $32.6 million for the second quarter, equal to $63.6 million in combined revenue. \n</p>\n<p>\n  The company's outlook implies a deceleration in revenue for the second quarter after it guided for a first-quarter topline performance of more than $33 million. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2025 11:31 ET (15:31 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CorMedix Shares Plunge After 1H Guidance Missed Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorMedix Shares Plunge After 1H Guidance Missed Expectations\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-03-25 23:31</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of CorMedix Tuesday dropped after the company's outlook for the first half of 2025 disappointed investors despite beating expectations in the fourth quarter. \n</p>\n<p>\n  The stock was down 31% at $7.39 in morning trading, on pace for the largest percent decrease since Aug. 22, when it fell 57%. Shares have dropped 80% over the past 12 months. \n</p>\n<p>\n  The biopharmaceutical company said it expects revenue between $50 million to $60 million for the first half. Analysts polled by FactSet are forecasting revenue of $31 million for the first quarter and $32.6 million for the second quarter, equal to $63.6 million in combined revenue. \n</p>\n<p>\n  The company's outlook implies a deceleration in revenue for the second quarter after it guided for a first-quarter topline performance of more than $33 million. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2025 11:31 ET (15:31 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2522001807","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522001807","pubTimestamp":1742916660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of CorMedix Tuesday dropped after the company's outlook for the first half of 2025 disappointed investors despite beating expectations in the fourth quarter.The stock was down 31% at $7.39 in morning trading, on pace for the largest percent decrease since Aug. 22, when it fell 57%. Shares have dropped 80% over the past 12 months.The biopharmaceutical company said it expects revenue between $50 million to $60 million for the first half. Analysts polled by FactSet are forecasting revenue of $31 million for the first quarter and $32.6 million for the second quarter, equal to $63.6 million in combined revenue.The company's outlook implies a deceleration in revenue for the second quarter after it guided for a first-quarter topline performance of more than $33 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CRMD":"CorMedix Inc."},"translate_title":"上半年指引未达预期后CorMedix股价暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":0.9},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Shares of CorMedix Tuesday dropped after the company's outlook for the first half of 2025 disappointed investors despite beating expectations in the fourth quarter. \n\n\n  The stock was down 31% at $7.39 in morning trading, on pace for the largest percent decrease since Aug. 22, when it fell 57%. Shares have dropped 80% over the past 12 months. \n\n\n  The biopharmaceutical company said it expects revenue between $50 million to $60 million for the first half. Analysts polled by FactSet are forecasting revenue of $31 million for the first quarter and $32.6 million for the second quarter, equal to $63.6 million in combined revenue. \n\n\n  The company's outlook implies a deceleration in revenue for the second quarter after it guided for a first-quarter topline performance of more than $33 million. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2025 11:31 ET (15:31 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}